申请人:Praecis Pharmaceuticals Incorporated
公开号:EP2441757A1
公开(公告)日:2012-04-18
The present invention provides, at least in part, compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, x, y, R2, R3, R4a, R5, R6 and R7 are described herein, as well as methods for their identification, their preparation, pharmaceutical compositions containing them, and their use as Aurora A kinase inhibitors in treatment, e.g., of cancer and other proliferative disorders.
A compound selected from:
or a pharmaceutically acceptable salt thereof.
本发明至少部分提供了式I化合物:或其药学上可接受的盐,其中Z1、Z2、Z3、R1、x、y、R2、R3、R4a、R5、R6和R7在本文中有所描述,还提供了它们的鉴定方法、制备方法、含有它们的药物组合物,以及它们作为极光A激酶抑制剂在治疗癌症和其他增殖性疾病等方面的用途。
化合物选自
或其药学上可接受的盐。